RxDoctor Payments Data

Amir Moasser, MD

Nephrology · Glendale, AZNPI 1932102530

Payments from drug & device makers

$4,949in general payments, 2019–2025

Across 254 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$846
  • Otsuka America Pharmaceutical, Inc.$626
  • Amgen$323
  • Mallinckrodt Hospital Products Inc.$307
  • OPKO Pharmaceuticals, LLC$286
  • Calliditas Therapeutics US Inc.$273
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,82297%
  • Education$1283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,949 in reported general payments places this provider in the 70th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$165,136
Medicare patients
399
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide45$127,966
VeltassaPatiromer Calcium Sorbitex14$18,327
Sevelamer Carbonate63$13,686
Lanthanum Carbonate11$12,737
LokelmaSodium Zirconium Cyclosilicate16$10,234
Tacrolimus29$3,893
Fluconazole44$2,546
Hydralazine Hcl186$2,179
Midodrine Hcl12$1,652
Bumetanide25$1,028
Amlodipine Besylate161$999
Potassium Chloride53$993
Furosemide111$716
Mycophenolate Mofetil15$631
Nifedipine ErNifedipine37$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$20$127,96645 claims
AstraZenecaLokelma$846$10,23416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 259 nephrology providers in Arizona.

Other nephrology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →